Occurrence of Venous Thromboembolism in Patients with Lung Cancer and Its Anticoagulant Therapy
Lung cancer is the first leading cause of morbidity and mortality in the world. Venous thromboembolism (VTE) is a recognized complication in patients with lung cancer, which is one of the leading cause of death in lung cancer patients. The cancer-related, patient-related and treatment-related factor...
Main Authors: | , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-10-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.09 |
id |
doaj-5dff54a499e444cca47cabb7e0988dac |
---|---|
record_format |
Article |
spelling |
doaj-5dff54a499e444cca47cabb7e0988dac2020-11-25T01:39:11ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872018-10-01211078478910.3779/j.issn.1009-3419.2018.10.09Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant TherapyHui DU0Jun CHEN1Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, ChinaLung cancer is the first leading cause of morbidity and mortality in the world. Venous thromboembolism (VTE) is a recognized complication in patients with lung cancer, which is one of the leading cause of death in lung cancer patients. The cancer-related, patient-related and treatment-related factors are the main causes of VTE in lung cancer patients. Malignant cells can directly activate blood coagulation by producing tissue factor (TF), cancer procoagulance (CP), inflammatory factors and cytokines; And the one of predominant mechanisms in cancer-related thrombosis is the overexpression of TF. The 10th edition of the antithrombotic therapy guidelines for VTE with cancer patients (AT-10) published in 2016 by American College of Chest Physicians (APCC) recommended that anticoagulant therapy is the basic treatment for patients with lung cancer complicated with VTE; And low molecular-weight-heparin (LMWH) is preferred as an anticoagulant drug, but can be use with caution due to increasing risk of bleeding.http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.09Lung neoplasmsVenous thromboembolism (VTE)OccurrenceAnticoagulant therapyLow molecular weight heparin (LMWH) |
collection |
DOAJ |
language |
zho |
format |
Article |
sources |
DOAJ |
author |
Hui DU Jun CHEN |
spellingShingle |
Hui DU Jun CHEN Occurrence of Venous Thromboembolism in Patients with Lung Cancer and Its Anticoagulant Therapy Chinese Journal of Lung Cancer Lung neoplasms Venous thromboembolism (VTE) Occurrence Anticoagulant therapy Low molecular weight heparin (LMWH) |
author_facet |
Hui DU Jun CHEN |
author_sort |
Hui DU |
title |
Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant Therapy |
title_short |
Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant Therapy |
title_full |
Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant Therapy |
title_fullStr |
Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant Therapy |
title_full_unstemmed |
Occurrence of Venous Thromboembolism in Patients with Lung Cancer
and Its Anticoagulant Therapy |
title_sort |
occurrence of venous thromboembolism in patients with lung cancer
and its anticoagulant therapy |
publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
series |
Chinese Journal of Lung Cancer |
issn |
1009-3419 1999-6187 |
publishDate |
2018-10-01 |
description |
Lung cancer is the first leading cause of morbidity and mortality in the world. Venous thromboembolism (VTE) is a recognized complication in patients with lung cancer, which is one of the leading cause of death in lung cancer patients. The cancer-related, patient-related and treatment-related factors are the main causes of VTE in lung cancer patients. Malignant cells can directly activate blood coagulation by producing tissue factor (TF), cancer procoagulance (CP), inflammatory factors and cytokines; And the one of predominant mechanisms in cancer-related thrombosis is the overexpression of TF. The 10th edition of the antithrombotic therapy guidelines for VTE with cancer patients (AT-10) published in 2016 by American College of Chest Physicians (APCC) recommended that anticoagulant therapy is the basic treatment for patients with lung cancer complicated with VTE; And low molecular-weight-heparin (LMWH) is preferred as an anticoagulant drug, but can be use with caution due to increasing risk of bleeding. |
topic |
Lung neoplasms Venous thromboembolism (VTE) Occurrence Anticoagulant therapy Low molecular weight heparin (LMWH) |
url |
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.10.09 |
work_keys_str_mv |
AT huidu occurrenceofvenousthromboembolisminpatientswithlungcanceranditsanticoagulanttherapy AT junchen occurrenceofvenousthromboembolisminpatientswithlungcanceranditsanticoagulanttherapy |
_version_ |
1725049985121124352 |